Bayer and Zydus cadila had announced and signed to form Joint venture in India named Bayer Zydus Pharma on 28.1.11. named Bayer Zydus Pharma.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 15,988 million (2009), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries.
Zydus Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. At the recently held Economic Times Awards for Corporate Excellence, Zydus Cadila won the award for the ‘Emerging Company of the Year’. The group employs over 12,000 people worldwide and is dedicated to creating healthier communities globally.
The joint venture is helping Cadila leverage on strengths and explore the possibility of creating a common platform and built a pool of expertise.
For Bayer HealthCare the formation of Bayer Zydus Pharma was a crucial element of the company’s strategy to build a stronger presence in the emerging markets. They had aimed to significantly accelerate their capabilities to better serve the fast growing Indian market. The Indian deal was just Bayer’s latest effort to expand in emerging markets. For instance, the company intended to launch 20 new products in China over the next five years, aiming for as much as 20 percent growth in sales there.
Bayer Zydus Pharma is operating in key segments of the Indian pharma market with a focus on: women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology. The combined portfolio will encompass among others such popular brands as Glucobay, Xarelto, Nexavar and Yaz/Yasmin from Bayer HealthCare as well as products currently marketed by Zydus Cadila such as Euglim ,Progynova and Ultravist.
Through this transaction Bayer HealthCare and Zydus underlined the importance of the emerging markets, specifically India. Bayer HealthCare is significantly enhancing its marketing capabilities in India as part of its emerging market growth strategy.Zydus is maintaining its strong position in India and will strengthen its network with global healthcare players, including in relation to its manufacturing capabilities.Bayer Zydus Pharma built upon and significantly enhanced the existing relationship of both parties with long term goals.